Market Research Report
Europe Exosome Diagnostic and Therapeutic Market Forecast 2019-2027
|Published by||Inkwood Research||Product code||837248|
|Published||Content info||78 Pages
Delivery time: 2-3 business days
|Europe Exosome Diagnostic and Therapeutic Market Forecast 2019-2027|
|Published: May 13, 2019||Content info: 78 Pages||
The exosomes are cell-derived particles that are secreted upon the fusion of external vesicles with the plasma membrane. The global exosome diagnostic and therapeutic market by the Europe region was valued at $XX million in 2018 and is expected to capture $XX million revenue by the end of 2027 with a CAGR of 27.76% during the forecast period of 2019-2027.
The European exosome diagnostic and therapeutic market is in its infantile phase, and it had stood as the second leading market in the global exosome diagnostic and therapeutic market in 2018. In Europe, the rising prevalence of chronic diseases like that of cancer, cardiovascular, and other communicable diseases augmented with proliferated population and lifestyle deviations in the region has further driven the market growth.
System Biosciences (SBI), HansaBioMed Life Sciences Ltd. (acquired by Lonza), BioCat GmbH, Nanosomix Inc., Hitachi Chemical Diagnostics, Inc., Thermo Fisher Scientific Inc., Exosome Diagnostics Inc., Codiak BioSciences, Qiagen N.V., Aethlon Medical, Inc., Malvern Instruments Ltd., EVOX Therapeutics Ltd., Capricor Therapeutics, Inc., MBL International Corporation, and Sistemic Ltd. are the major companies operating in the market, which have been exhaustively profiled in the report.